Mimedx (MDXG) Long-Term Investments (2014 - 2015)

Mimedx (MDXG) reported Long-Term Investments of $2.5 million for Q1 2015, down 23.08% sequentially from $3.2 million in Q4 2014.

Mimedx (MDXG) Long-Term Investments (2014 - 2015) Analysis & Trends

Mimedx (MDXG) has 2 years of Long-Term Investments data on file, last reported at $2.5 million in Q1 2015.

For the quarter ending Q1 2015, Long-Term Investments changed N/A year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2015 stood at $2.5 million (changed N/A YoY), and the FY2014 full-year result was $3.2 million, changed N/A from the prior year.
Long-Term Investments eased to $2.5 million in Q1 2015, from $3.2 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $3.2 million in Q4 2014 to a low of $2.5 million in Q1 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Mimedx	615.09 Mn	455.31 Mn	41.62 Mn	-

Download Data

Date	Value
Mar 31, 2015	2.50 Mn
Dec 31, 2014	3.25 Mn